| Name | Title | Contact Details |
|---|---|---|
Ed Mangis |
Executive Vice President and Chief Learning and Talent Development Officer | Profile |
Kathryn Kenney |
VP, Talent Acquisition | Profile |
Allison Spriggs |
Vice President, Talent Acquisition | Profile |
Leslie Simpson |
EVP, Talent Acquisition Strategy | Profile |
Richard Garcia |
Chief Talent Officer for North America | Profile |
Radionetics Oncology is a pharmaceutical company focused on the discovery and development of novel radiotherapeutics for the treatment of a wide range of oncology indications. The company`s platform technology uses nonpeptide, small molecule targeting to deliver therapeutic radioisotopes to a broad range of cancers by binding selectively to peptide receptors that are selectively expressed on these tumors. This nonpeptide technology addresses many of the significant challenges currently facing peptide and protein targeted radiotherapeutics, particularly in the realm of optimizing drug-like characteristics and manufacturing. The company is rapidly advancing a pipeline of drug candidates to treat a broad range of cancers and is conducting additional drug discovery efforts to identify drug candidates for additional receptor targets in collaboration with Crinetics Pharmaceuticals.
Bridge Laboratories is a Gaithersburg, MD-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Cyteir is a clinical-stage oncology company that is focused on the discovery and development of next-generation synthetically lethal therapies to treat cancer. The company is using its expertise in DNA damage response biology to advance a pipeline of novel drug candidates that selectively target key cancer vulnerabilities. Cyteir`s wholly owned lead compound, CYT-0851, is a potent and selective, oral investigational drug currently in a Phase 1/2 clinical trial for hematologic and solid tumors.
Precision BioLogic is a Dartmouth, NS-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
PharmaMed Resources is a Kenilworth, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.